Health Care·Biotechnology·$351.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.82 | N/A | -1.09% |
management commentary, guidance changes, and full analysis available with Pro.
| -1.09% |
Tone: Cautiously Optimistic
Management expressed confidence in their long-term strategy despite the slight EPS miss. They highlighted the potential of their product pipeline.
We remain focused on our long-term growth strategy.
Our pipeline continues to show promise for future developments.
AbbVie's earnings report showed a slight miss on EPS, but the stock reacted positively, rising by 1.9%. Investors may have been encouraged by management's focus on long-term growth and the potential of their product pipeline, despite the lack of revenue data and guidance updates.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
NEXTERA ENERGY INC
Jan 28, 2014